Syndax Pharmaceuticals Inc Stock Price, News & Analysis

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to seven new employees under its 2023 Inducement Plan. The awards consist of stock options to purchase up to 48,600 shares of common stock.

The stock options feature a four-year vesting schedule, with 25% of shares vesting after one year and the remaining 1/48th vesting monthly over the subsequent 36 months, contingent on continued employment with Syndax.

Syndax Pharmaceuticals (NASDAQ:SNDX) reported strong Q2 2025 financial results, highlighting significant growth in its commercial portfolio. Revuforj generated $28.6M in net revenue, up 43% from Q1, while Niktimvo achieved $36.2M in net revenue in its first full quarter, contributing $9.4M in collaboration revenue to Syndax.

Key developments include FDA Priority Review for Revuforj's sNDA in R/R mNPM1 AML with a PDUFA date of October 25, 2025. The company maintains a strong financial position with $517.9M in cash and expects to reach profitability with stable operating expenses. Clinical data showed promising results, including a 48% overall response rate in R/R mNPM1 AML patients.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has scheduled its second quarter 2025 financial results announcement and business update for August 4, 2025.

The company will host a conference call and live audio webcast at 4:30 p.m. ET on the same day. Investors can access the event through the company's website or by dialing 800-590-8290 (domestic) or 240-690-8800 (international). A replay will be available on Syndax's website for 90 days after the call.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to 14 new employees. The awards consist of options to purchase up to 228,400 shares of common stock under the Company's 2023 Inducement Plan.

The stock options feature a four-year vesting schedule, with 25% vesting after one year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment with Syndax.

Syndax Pharmaceuticals (NASDAQ:SNDX) announced that the FDA has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj® (revumenib) to treat relapsed or refractory mutant NPM1 acute myeloid leukemia.

The FDA has set a PDUFA target action date of October 25, 2025. The sNDA is being reviewed under the FDA's Real-Time Oncology Review program. If approved, Revuforj would become the first and only menin inhibitor approved for both R/R mNPM1 AML and R/R KMT2Ar acute leukemia. The drug received initial FDA approval in 2024 for R/R acute leukemia with KMT2A translocation.

The sNDA submission is supported by positive pivotal data from the AUGMENT-101 trial, with results published in Blood and presented at the EHA Annual Congress Meeting.

Syndax Pharmaceuticals (SNDX) announced promising results from the BEAT AML trial testing revumenib combined with venetoclax/azacitidine in older patients with newly diagnosed mNPM1 and KMT2Ar acute myeloid leukemia (AML). The study showed impressive efficacy with a 67% complete remission rate, 88% overall response rate, and 100% MRD negativity among responders. The treatment was well-tolerated, with common side effects including nausea (60%), constipation (53%), and QTc prolongation (44%). The median overall survival reached 15.5 months, significantly better than historical data. The trial included 43 patients (median age 70 years), with 79% having mNPM1 AML and 21% KMT2Ar AML. These results support the ongoing Phase 3 EVOLVE-2 trial evaluating revumenib with ven/aza in newly diagnosed mNPM1 AML patients unfit for intensive chemotherapy.

Syndax Pharmaceuticals presented new data from the AUGMENT-101 trial of Revuforj (revumenib) at EHA 2025, showing promising results in treating relapsed/refractory mNPM1 and NUP98r acute leukemia. In the efficacy-evaluable pivotal R/R mNPM1 AML population (n=77), the treatment achieved a 26% CR+CRh rate and 48% overall response rate. The median overall survival was 4.8 months for all patients, extending to 23.3 months for responders. The drug demonstrated effectiveness across various subgroups, regardless of prior treatments. In Phase 1 R/R NUP98r AML patients, a 60% overall response rate was observed. Revuforj was generally well-tolerated, with only 4.8% of patients discontinuing due to treatment-related adverse events. The drug received FDA approval in November 2024 for R/R acute leukemia with KMT2A translocation.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to eight new employees. The awards consist of stock options to purchase up to 119,700 shares of common stock under the Company's 2023 Inducement Plan. The vesting schedule spans four years, with 25% of shares vesting after the first year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months. The vesting is contingent upon continued employment with Syndax.

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two major upcoming investor conferences in June 2025. CEO Michael A. Metzger and the management team will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 1:25 p.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 2:00 p.m. ET. Both presentations will be available via live webcast on the company's website investor section, with replays accessible for a limited time.